Ubs Asset Management Americas Inc Biocryst Pharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

$379 Billion
Q1 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 448,466 shares of BCRX stock, worth $5.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

448,466

Previous 401,111 11.81%

Holding current value

$5.02 Million

Previous $3.02 Million 11.51%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 19, 2025	BUY	$7.06 - $9.39 $334,326 - $444,663	47,355 Added 11.81%	448,466 $3.36 Million
Q4 2024 Feb 14, 2025	BUY	$7.03 - $8.43 $81,414 - $97,627	11,581 Added 2.97%	401,111 $3.02 Million
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $278,020 - $376,911	-43,373 Reduced 10.02%	389,530 $2.96 Million
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $767,886 - $1.26 Million	185,929 Added 75.28%	432,903 $2.68 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $51,856 - $70,496	10,413 Added 4.4%	246,974 $1.48 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $260,916 - $389,074	32,861 Added 16.13%	236,561 $1.97 Million
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $766 - $1,036	-73 Reduced 0.04%	203,700 $2.34 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $35,089 - $48,162	3,252 Added 1.62%	203,773 $2.57 Million
Q2 2022 Aug 12, 2022	SELL	$7.89 - $17.88 $241,662 - $547,646	-30,629 Reduced 13.25%	200,521 $2.12 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $310,120 - $530,101	26,827 Added 13.13%	231,150 $3.76 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $330,503 - $457,028	29,562 Added 16.92%	204,323 $2.83 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $840,265 - $1.04 Million	-59,132 Reduced 25.28%	174,761 $2.51 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $4,560 - $8,275	480 Added 0.21%	233,893 $3.7 Million
Q1 2021 May 14, 2021	SELL	$7.37 - $13.61 $141,592 - $261,475	-19,212 Reduced 7.6%	233,413 $2.37 Million
Q4 2020 Mar 01, 2021	SELL	$3.37 - $8.61 $3.06 Million - $7.82 Million	-908,530 Reduced 78.24%	252,625 $1.88 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $1.99 Million - $5.86 Million	1,044,870 Added 898.54%	1,161,155 $5.53 Million
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $18,219 - $46,800	-11,387 Reduced 8.92%	116,285 $232,000
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $85,745 - $186,051	53,928 Added 73.13%	127,672 $440,000
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $19,465 - $29,041	7,786 Added 11.8%	73,744 $211,000
Q2 2019 Aug 15, 2019	BUY	$2.91 - $9.15 $13,976 - $43,947	4,803 Added 7.85%	65,958 $0
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $96,869 - $127,584	13,126 Added 27.33%	61,155 $0
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $56,055 - $79,452	-12,186 Reduced 20.24%	48,029 $0
Q1 2018 May 14, 2018	BUY	$4.35 - $5.82 $78,430 - $104,934	18,030 Added 42.74%	60,215 $0
Q3 2017 Nov 13, 2017	BUY	$4.1 - $5.97 $172,958 - $251,844	42,185	42,185 $0

Others Institutions Holding BCRX

# of Institutions

293

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $2.08B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Biocryst Pharmaceuticals Inc Transaction History